| Fms样酪氨酸激酶抑制剂治疗急性髓性白血病的新进展 |
| |
| 引用本文： | 王蓓丽,徐建民. Fms样酪氨酸激酶抑制剂治疗急性髓性白血病的新进展[J]. 中国新药与临床杂志, 2005, 24(10): 812-817 |
| |
| 作者姓名： | 王蓓丽 徐建民 |
| |
| 作者单位： | 复旦大学附属中山医院,血液科,上海,200032 |
| |
| 摘 要： | Fms样酪氨酸激酶(FLT3)属于Ⅲ型受体酪氨酸蛋白激酶家族,其异常表达见于大部分急性髓性白血病(AML)病人,包括野生型受体与配体的协同表达,内部串连复制及活化环突变,表达持续性磷酸化活化的FLT3,对预后的判断具有重要意义。FLT3抑制剂主要有5类及热休克蛋白90抑制剂,实验室研究与初步的临床试验显示出其对AML的治疗价值。
|
| 关 键 词： | 白血病,粒细胞,急性 点突变 蛋白质酪氨酸激酶 |
| 文章编号： | 1007-7669（2005）10-0812-06 |
| 收稿时间： | 2004-11-30 |
| 修稿时间： | 2004-11-302005-07-27 |
Progress of treatment with Fms-like receptor tyrosine kinase-3 inhibitors for acute myelogenous leukemia |
| |
| WANG Bei-li,XU Jian-min. Progress of treatment with Fms-like receptor tyrosine kinase-3 inhibitors for acute myelogenous leukemia[J]. Chinese Journal of New Drugs and Clinical Remedies, 2005, 24(10): 812-817 |
| |
| Authors: | WANG Bei-li XU Jian-min |
| |
| Affiliation: | Department of Hematology, Zhongshan Hospital, Fu- dan University, SHANGHAI 200032, China |
| |
| Abstract: | Fms-like receptor tyrosine kinase-3 (FLT3) is a member of the class Ⅲ receptor tyrosine kinase family. Coexpression of wild-type receptor with its ligand,internal tandem duplications (ITD) and activation loop mutations lead to the consistent expression of phosphorylation-activited FLT3. These aberrant expressions of FLT3 have been detected in most acute myelogenous leukemia (AML) providing a prognostic significance. FLT3 inhibitors mainly include 5 varieties and heat shock protein 90(HSP90)inhibitor as well. These agents have shown promising effect on the therapy of AML in experiments and early clinical trials. |
| |
| Keywords: | leukemia, myelocytic, acute point mutation protein-tyrosine kinase |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
